INTRODUCTION
Giardia intestinalis, also known as Giardia duodenalis or Giardia lamblia, is a
unicellular protozoan parasite that infects the upper intestinal tract of humans and animals [1]. The disease, giardiasis, manifests in humans as a bout of acute diarrhea that can develop to a chronic stage but the majority of infections remain asymptomatic [2, 3]. Giardiasis has a global distribution with 280 million cases reported annually, with its impact being more pronounced in the developing world, where it is usually associated with poor socioeconomic conditions [4]. Children, elderly people and immunocompromised individuals are the most affected by the disease [5 - 7]. In children specifically, effects on growth, nutrition and cognitive function have been reported [8 - 10]. Currently, it has been suggested that giardiasis could predispose for chronic gastrointestinal disorders such as irritable bowel syndrome (IBS) [11, 12]. In 2004, giardiasis was recognized by the World Health Organization (WHO) as a neglected disease associated with poverty, impairing development and socio-economic improvements [13]. Because giardiasis adds to the global microbial disease burden, an initiative was instigated to implement a comprehensive approach for control and prevention [13]. One area of focus is the potential spread of giardiasis via food and food handling [14, 15], daycare settings [16, 17], travel to endemic areas and close human contact [18 - 20]. Potential transmission of giardiasis from animals to humans (i.e. zoonosis) has been also the subject of extensive research over the years. Wildlife accessibility to water used for drinking and recreational purposes, as well as living in proximity with animals, have been identified as risk factors associated with zoonosis [21 - 23]. Another body of research addressed the effect of giardiasis on livestock. Not only transmission in livestock but also economic losses associated with poor growth, weight loss, reduced productivity and even death of animals [24 - 28]. Thus, giardiasis is regarded as a disease that has a significant impact on both humans and animals.
Currently, there are eight different genotypes, also called assemblages, of G. intestinalis. Giardia assemblages are designated from A to H, the majority of which are host-specific [7]. Parasites that belong to assemblages A and B infect humans but are also common in other mammals [29]. The Giardia life cycle alternates between an actively dividing trophozoite and an infectious cyst. Cysts are transmitted to humans via the fecal-oral route and upon ingestion they break open (i.e. excyst) in the duodenum, releasing trophozoites [29]. Trophozoites attach to the intestinal epithelial cells (IECs), to avoid elimination by peristalsis, and start multiplication. The presence of Giardia in the host intestines and in close contact with IECs induce functional and structural changes in the intestinal epithelia, which overall results in diarrhea [30]. Nevertheless, given the variability in giardiasis symptoms, infection versus symptoms or lack of symptoms is a controversial issue where the interplay between the infecting parasite of a certain assemblage, isolate virulence and host factors could determine the outcome of infection.
Giardia does not cause overt inflammation in the host small intestines during most infections [31 - 33]. However, inflammatory responses have been seen during acute experimental and human infections [34, 35]. In line with this, IECs produce proinflammatory cytokines in response to the parasite or parasite-excreted products in an isolate-specific mode of induction [36]. At the same time, some parasite factors such as cysteine proteases (CPs) have been shown to attenuate the proinflammatory response by cytokine degradation [37]. Indeed, an accumulating body of evidence shows that cytokine production is rather inhibited during giardiasis [38 - 41]. Effector mechanisms play an early part in defense against Giardia and these include nitric oxide (NO) production, lactoferrins, α-defensins, phagocytes, mast cells and dendritic cells [31, 42]. The parasite, however, is able to avert some of these responses, specifically, NO production [43], dendritic cells recruitment [44] and granulocyte infiltration [45]. Patients are able to clear the infection within few weeks and re-infections manifest with reduced symptoms, indicating an acquired immunity against giardiasis [46 - 48]. Antibodies (i.e. B cell response) have been suggested to be important players in parasite clearance while the contribution of T cell responses is still unclear [31, 42].
Identification of cysts by microscopy is the gold standard in diagnosing human giardiasis. This is because trophozoites are only seen in stool during periods of acute diarrhea (i.e. watery or loose stool). Bright field microscopy coupled with morphometry, using phase contrast or differential interference contrast, is performed on wet mounts or following sample concentration [49]. Usually, multiple stool samples are submitted for analysis, especially when neither trophozoites nor cysts could be detected microscopically at initial examination. Fixation and staining can maintain trophozoite morphology and enhance visualizing trophozoite structure [49]. Antigen detection in stool (coproantigen) can be used for large-scale analyses and polymerase chain reaction (PCR) for increased sensitivity and specificity as well as genotyping [49]. For environmental samples, an initial filtration step is included to concentrate cysts in water samples. Immunomagnetic separation (IMS) followed by fluorescent microscopy is the gold standard for detecting cysts and is used for dual detection of Giardia cysts and Cryptosporidium oocysts in different water matrices [50]. The technique uses antibodies immobilized to magnetic beads to capture cysts in concentrated samples and fluorescence isothiocyanate (FITC)-linked antibodies to view cysts by fluorescent microscope [50]. The same method is adopted for food, specifically fruit and vegetables, using different wash buffers and sometimes stom...